| Hazard Information | Back Directory | [Uses]
[D-Ala2]-Met-Enkephalinamide, an opioid peptide, is a potent opioid agonist. [D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism. [D-Ala2]-Met-Enkephalinamide has analgesic properties[1][2]. | [in vivo]
[D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism in Sprague-Dawley rats[1]. | Animal Model: | Male Sprague-Dawley rats (250-320 g)[1] | | Dosage: | 10, 50, 100, 150, and 200 mg/kg | | Administration: | Intracerebroventrical injection | | Result: | Decreased in bile flow that ranged from 12% to 41%.
Decreased bicarbonate secretion into bile.
|
| [References]
[1] Bergasa NV, et, al. The opioid peptide analog D-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism. Peptides. 1999;20(8):979-86. DOI:10.1016/s0196-9781(99)00091-1
[2] PERT CB, et, al. [D-Ala2]-Met-Enkephalinamide: A Potent, Long-Lasting Synthetic Pentapeptide Analgesic. 1976 Oct 15;194(4262):330-2. |
|
| Company Name: |
Nextpeptide Inc
|
| Telephone: |
+86-0571-81612335 +8613336028439 |
| Website: |
http://www.nextpeptide.com/ |
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|